title: Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?
abstract: There is now a considerable body of data supporting the hypothesis that aspirin could be effective in the prevention and treatment of colorectal cancer, and a number of phase III randomised controlled trials designed to evaluate the role of aspirin in the treatment of colorectal cancer are ongoing. Although generally well tolerated, aspirin can have adverse effects, including dyspepsia and, infrequently, bleeding. To ensure a favourable balance of benefits and risks from aspirin, a more personalised assessment of the advantages and disadvantages is required. Emerging data suggest that tumour PIK3CA mutation status, expression of cyclo-oxygenase-2 and human leukocyte antigen class I, along with certain germline polymorphisms, might all help to identify individuals who stand to gain most. We review both the underpinning evidence and current data, on clinical, molecular and genetic biomarkers for aspirin use in the prevention and treatment of colorectal cancer, and discuss the opportunities for further biomarker research provided by ongoing trials.
authors.affiliation: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Coyle
authors.affiliation: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH UK.
authors.forename: Fay Helen
authors.initials: FH
authors.lastname: Cafferty
authors.affiliation: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH UK.
authors.forename: Ruth Elizabeth
authors.initials: RE
authors.lastname: Langley
keywords: Acetylsalicylic acid; Adjuvant therapy; Aspirin; BRAF; Bleeding; Chemoprevention; Colorectal cancer; Human leukocyte antigen; NSAID; PIK3CA; Primary prevention; Secondary prevention; Single-nucleotide polymorphism